Compare Abeona Therapeutics Inc (ABEO) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Microchip Technology Inc. — how do they compare? Abeona Therapeutics Inc trades at $7.31 (market cap $421.19M), while Microchip Technology Inc. trades at $82.5 (market cap $43.99B). The key difference: Microchip Technology Inc. is far larger — about 104.4× Abeona Therapeutics Inc's market cap, and Microchip Technology Inc. pays a 2.25% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MCHP | |
|---|---|---|
Market Cap | $421.19M | $43.99B |
Sector | Health | Technology |
52-Week High | $7.45 | $102.97 |
52-Week Low | $4.17 | $49.02 |
Enterprise Value | $276.10M | $49.12B |
Dividend Yield | — | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Microchip Technology (MCHP) trades at $81.39, down 3.9% on the day, amid a bullish technical setup and strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.76 exceeding expectations. Recent news highlights robust data center revenue growth (98% last quarter) and strategic acquisitions like Hailo to bolster edge AI capabilities. Valuation metrics remain elevated with a P/E of 119.15, reflecting high growth expectations.
MCHP's outlook is positive with expanding AI infrastructure demand and raised guidance, though high valuation and recent net income pressure in 2025 pose risks. The consensus price target of $104 suggests 28% upside potential. Key risks include execution on growth initiatives and semiconductor cycle volatility. Institutional sentiment remains strongly bullish with no sell ratings among 44 analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
